Non-GLP and Discovery Bioanalysis

The speed of lead candidate selection studies requires an equally rapid analytical tool to efficiently measure drug concentrations in the biological samples collected. Charles River offers non-GLP and discovery bioanalytical services, either in support of studies conducted in-house or as a stand-alone service, with the flexibility to meet the timelines and diverse needs for discovering the best drug candidate.

Our research-grade assay approach via LC-MS/MS can quickly analyze samples for compound ranking. Once a lead candidate has been selected in the discovery analytical process, these methods can be transferred to method development for GLP bioanalytical testing including feasibility, validation, and preclinical and clinical sample analysis.

Our Approach

In discovery bioanalysis, the lab is often blind to analyte structure. To proceed quickly and intelligently, we start with a default protein precipitation LC-MS/MS method that is applicable to the vast majority of small molecule compounds, eliminating the need for method development or qualification. Features of the methodology include:

  • Assay range of 1–5000 ng/mL (default; can be modified as required)
  • Front and back calibration standards consisting of nine different concentrations
  • Sample aliquot volume default of 10 µL of biofluid (particularly important for serial mouse sampling)
  • Addition of gradient selection based on retention time

The use of bracketing calibration standards is crucial in discovery to control potential divergence (drift) that can occur due to buildup of matrix components or dosing vehicle. This effort is further aided by our use of small sample volumes, which minimize these adverse effects, plus our use of the latest technologies, such as UPLC and Tandem MS (MS/MS), to achieve appropriate sensitivity even with such small sample aliquots.

Research-Grade Assays
Diagnostic Probes

You may also be interested in...

Biomarker Services

We can support your drug discovery pipeline by providing biomarker analysis in a non-GxP environment.


We provide an integrated approach to PK studies where study directors act as the single point of contact and are engaged from formulation to data delivery.